Navigation Links
Endo Pharmaceuticals and Alexza Pharmaceuticals Conclude Research Collaboration
Date:1/29/2009

n patients requiring continuous, around-the-clock opioid treatment for an extended period of time; and VOLTAREN(R) gel, a nonsteroidal anti-inflammatory drug indicated for the relief of the pain of osteoarthritis of joints amenable to topical treatment. The company markets its branded pharmaceutical products to physicians in pain management, neurology, surgery, oncology, and primary care. More information, including this and past press releases of Endo Pharmaceuticals, is available at www.endo.com.

Safe Harbor Statement

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements including words such as "believes," "expects," "anticipates," "intends," "estimates," "plan," "will," "may," "intend," "guidance" or similar expressions are forward-looking statements. Because these statements reflect our current views, expectations and beliefs concerning future events, these forward-looking statements involve risks and uncertainties. Investors should note that many factors could affect our future financial results and could cause our actual results to differ materially from those expressed in forward-looking statements contained in this press release. Risks and uncertainties include the satisfaction of closing conditions for the acquisition, including clearance under the Hart-Scott-Rodino Antitrust Improvements Act; the tender of a majority of the outstanding shares of common stock of Indevus; the possibility that the transaction will not be completed, or if completed, not completed on a timely basis; the possibility that the acquisition of Indevus is not complementary to Endo; the potential that market segment growth will not follow historical patterns; general industry conditions and competition; business and economic conditions, such as interest rate and currency exchange rate fluc
'/>"/>

SOURCE Endo Pharmaceuticals
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... and SAN DIEGO , Dec. 17, ... PHG ; AEX: PHIA) and Volcano Corporation (NASDAQ: ... solutions for cardiovascular applications, today announced that they have entered ... will commence a tender offer to acquire all of the ... share, or a total equity purchase price of USD 1 ...
(Date:12/17/2014)... , Dec. 17, 2014 With ... (MRI), the MRI market is seeing new growth, ... breast MRI scans account for the majority of ... higher resolution of images, which are creating opportunities for ... (MRI) market is growing at a rate of ...
(Date:12/17/2014)... MARLBOROUGH, Mass. , Dec. 17, 2014 /PRNewswire/ ... a biotechnology company focused on discovering, developing and ... using RNA-targeted technologies, today announced completion of enrollment in ... results from the 3-month observations confirmed the 1-month ... year:  Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ...
Breaking Medicine Technology:Philips to acquire Volcano to expand global leadership position in image-guided therapy market 2Philips to acquire Volcano to expand global leadership position in image-guided therapy market 3Philips to acquire Volcano to expand global leadership position in image-guided therapy market 4Philips to acquire Volcano to expand global leadership position in image-guided therapy market 5Philips to acquire Volcano to expand global leadership position in image-guided therapy market 6Philips to acquire Volcano to expand global leadership position in image-guided therapy market 7Philips to acquire Volcano to expand global leadership position in image-guided therapy market 8Kalorama: 3T Advancements Bringing New Growth to the MRI Market 2Kalorama: 3T Advancements Bringing New Growth to the MRI Market 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5
... The AXA Research Fund closed out its first year ... than Euro 13 million to various European research institutions.The purpose ... of major risks in the world by supporting cutting edge ... Euro 100 million over five years, making it a major ...
... Research features from Mayo ClinicROCHESTER, Minn., March 23 ... of Discovery,s Edge, Mayo Clinic,s research magazine. You ... often as you wish. Reprinting is allowed with ... as your editorial policies permit: Visit http://discoverysedge.mayo.edu ...
Cached Medicine Technology:First Year Results of the AXA Research Fund: Over Euro 13 Million Allocated for Research in 2008 2First Year Results of the AXA Research Fund: Over Euro 13 Million Allocated for Research in 2008 3Discovery's Edge Spring Issue - http://discoverysedge.mayo.edu 2
(Date:12/20/2014)... 20, 2014 An improving macroeconomic landscape ... benefited the Massage Services industry over the ... industry products, the anticipated 1.0% annualized increase in per ... consumers with the means to afford additional massages. “While ... massage in a given year has declined from 2009 ...
(Date:12/20/2014)... December 20, 2014 DePuy Pinnacle ... metal-on-metal version of the artificial hip system was ... and federal courts, Bernstein Liebhard LLP reports. According ... County Superior Court on December 2nd, counsel in ... deposition of plaintiffs on November 19, 2014, with ...
(Date:12/20/2014)... 2014 (HealthDay News) -- The holidays can be anything ... with fresh trees, scented candles and other allergy triggers. ... decorations that have been packed away in dank basements ... and asthma patients," Dr. Rachna Shah, an affiliate faculty ... said in Loyola news release. Shah, who is ...
(Date:12/20/2014)... 20, 2014 The Doctor’s Office Urgent Care ... better part of a decade. They’ve treated over 40,000 ... faster healthcare alternative to the Paramus area. ... new additions to their staff of top-notch board certified physicians: ... MD. These new doctors will work tirelessly to ...
(Date:12/20/2014)... December 20, 2014 As Risperdal ... forward in U.S. courts, Bernstein Liebhard LLP notes ... that children treated with the medication may experience ... breast development and lactation. The study, which appears ... and adolescents who began treatment with risperidone, an ...
Breaking Medicine News(10 mins):Health News:Massage Services in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Massage Services in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 2Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 3Health News:New Jersey Court Overseeing DePuy Pinnacle Hip Lawsuits Issues New Order, Bernstein Liebhard LLP Reports 4Health News:Holiday Trimmings Can Trigger Allergies 2Health News:The Doctor's Office Urgent Care Adds 3 New Physicians to Their Growing Medical Team 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 2Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 3Health News:Risperdal Lawsuit News: Bernstein Liebhard LLP Notes Publication of Study Suggesting Medication May Raise Prolactin Levels in Children 4
... Neurosurgeons from NYU Langone Medical Center will present research ... to treat neurosurgical conditions at the annual meeting of ... 14-18, 2012 in Miami Beach, FL. NYU Langone faculty ... at AANS, including: *Craino-Cervical and C1C2 Stabilization ...
... Virginia Commonwealth University School of Medicine researchers have discovered ... may contribute to high blood pressure and increase susceptibility to ... findings could provide clues to the best treatment approaches for ... can block blood flow to a pregnant woman,s internal organs ...
... Steven Reinberg HealthDay Reporter , THURSDAY, April ... called phthalates, which are found in soaps, lotions, plastics ... diabetes among older adults, Swedish researchers say. "Our ... contribute to the development of diabetes," said lead researcher ...
... , THURSDAY, April 12 (HealthDay News) -- Genetic evidence ... a new study says. The finding is significant because ... not, the researchers explained. The researchers compared the number ... life-cycle stage of head and body lice and found that ...
... in how exercise affects menopausal women, according to Penn ... one experiences more hot flashes after physical activity, while ... that seemed to differentiate the two groups was perceived ... of kinesiology. "These women have ways of dealing with ...
... Dotinga HealthDay Reporter , THURSDAY, April 12 (HealthDay ... stress, a new study from Denmark finds that the marriages ... likely to fall apart. The study debunks "a persistent ... one,s marriage and family. This is simply not true," said ...
Cached Medicine News:Health News:NYU Langone experts present research, clinical advances at neurosurgeons meeting 2Health News:Changes in gene expression may help explain high blood pressure in pregnancy 2Health News:Common Plastics Chemical Might Boost Diabetes Risk 2Health News:Common Plastics Chemical Might Boost Diabetes Risk 3Health News:Exercise and attitude may be thermostat for hot flashes 2Health News:Parents of Kids With Cancer No More Likely to Break Up 2
The MPM-1 offers a broad range of functions to attain new levels of parenchymal and ventricular monitoring through fiberoptic technology at the source....
The IVR-Optical Tracking system is engineered for easy calibration. This procedure can be done within five minutes by trained personnel, and is the only calibration required....
Slightly curved blunt dissector, double-ended. Length 11 1/2" (272 mm)...
Penfield Dissector #2...
Medicine Products: